Farmas USA

Framus
Aquí tienes la mini cuňa descendente que antier veías tu

SYNERGY PHARMACEUTICALS ANNOUNCES LICENSE AGREEMENT WITH LUOXIN PHARMACEUTICAL GROUP FOR TRULANCE® (PLECANATIDE) IN CHINA

https://ir.synergypharma.com/press-releases/detail/1872

Aún no los he podido leer, solo he visto -1.30 EPS.

http://globenewswire.com/news-release/2018/08/07/1547909/0/en/Melinta-Therapeutics-Reports-Second-Quarter-2018-Financial-Results.html

MLNT

Melinta Therapeutics Reports Second Quarter 2018 Financial Results

Solid Performance from New Product Launches

VabomereTM Granted NTAP Status by CMS

Strengthened Financial Position Supports Continued Growth

Completed Expansion and Cross-Training of Experienced Anti-infective Sales Force

Q2 2018 and Recent Business Highlights

• Completed the hiring of 71 additional field sales personnel bringing total sales representatives to 170
• Completed realignment and cross-training of experienced anti-infective sales force across all four products, including Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection
• Made strong progress on hospital approval process of new launches, Vabomere and Baxdela
• Vabomere granted New Technology Add-On Payment (NTAP) by Centers for Medicare & Medicaid Services (CMS), effective Oct. 1, 2018
• Continued growth in retail market for Baxdela, driven by specialty retail focus of our sales force
• Completed enrollment ahead of schedule for Baxdela Phase III trial for treatment of adults with community acquired bacterial pneumonia (“CABP”)
• Entered into partnership with CARB-X, receiving up to approximately $6 million to help advance pre-clinical and clinical development of a novel antibiotic class
• Launched new antibiotic stewardship program designed to address the growing threat of antimicrobial resistance
• Completed follow-on public offering of shares of common stock, raising approximately $115 million in net proceeds
• Demonstrated breadth of commercial and clinical programs with 20 presentations at the American Society of Microbiology’s ASM Microbe 2018 meeting

2018 Upcoming Potential Catalysts

• Pivotal Phase 3 data for Baxdela in CABP
• Vabomere EMA regulatory approval decision
• Vabomere Medicare NTAP status effective Oct. 1, 2018
• Additional ex-U.S. submissions for Baxdela in Central and South America
• Ex-U.S. partnership opportunities for Vabomere, Orbactiv and Minocin for Injection
• Additional data and publications at ID Week
• IND-enabling studies for the lead ESKAPE compound

http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-reports-second-quarter-2018-financial

Mlnt

De lo de doblar pérdidas respecto al trimestre anterior no lo dice en sus business highlights no? Nada más que añadir...

Tgtx
De sus ER:
Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in MS.

Final data from Phase 2 MS study at a major medical conference before year end.

Me vale para seguir confirmando esta teoría: " Si un stock da un subidón sin motivo aparente, la jornada antes de presentar los resultados trimestrales, es que éstos van a ser muy malos".

MLNT

Y tambien me vale para AKAO, que pegó un subidon a final de la sesión después de estar todo el rato en rojo.

Eso mismo pienso yo podria suceder con SGYP, ..como ahora 2 dia antes del ER sueltan esa Good News de acuerdos en China  

Supongo que esa teoría va acompañada de volúmenes bajos